<DOC>
	<DOCNO>NCT02283762</DOCNO>
	<brief_summary>To investigate Riociguat effective treatment systemic sclerosis</brief_summary>
	<brief_title>Efficacy Safety Riociguat Patients With Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Men woman age 18 year old Systemic sclerosis , define ACR/EULAR ( American College Rheumatology/European League Against Rheumatism ) 2013 criterion dcSSc ( diffuse cutaneous systemic sclerosis ) accord LeRoy criterion , ie , skin fibrosis proximal elbow knee addition acral fibrosis Disease duration ≤ 18 month ( defined time first non−Raynaud 's phenomenon manifestation ) ≥ 10 ≤ 22 mRSS ( modify Rodnan skin score ) unit screen visit FVC ( force vital capacity ) ≥ 45 % predict screen DLCO ( diffusion capacity lung carbon monoxide ) ≥ 40 % predict ( hemoglobincorrected ) screen Negative serum pregnancy test woman childbearing potential screen visit Women childbearing potential must agree use adequate contraception sexually active . `` Adequate contraception '' define combination least 2 effective method birth control , least 1 physical barrier ( e.g . condom hormonal contraception like implant combine oral contraceptive , condom intrauterine device ) . This apply since sign informed consent form 30 ( +5 ) day last study drug administration . Limited cutaneous SSc ( systemic sclerosis ) screen Major surgery ( include joint surgery ) within 8 week prior screen Hepatic insufficiency classify ChildPugh C Patients isolate AST ALT &gt; 3xULN bilirubin &gt; 2xULN included trial condition additional monitoring trial Estimated glomerular filtration rate ( eGFR ) &lt; 15 mL/min/1.73m2 ( Modification Diet Renal Disease formula ) dialysis screen visit . Patients enter trial eGFR 1529 mL/min/1.73m2 undergo additional monitoring renal function Any prior history renal crisis Sitting SBP ( systolic blood pressure ) &lt; 95 mmHg screen visit Sitting heart rate &lt; 50 beat per minute ( BPM ) screen visit Left ventricular ejection fraction &lt; 40 % prior screen Any form pulmonary hypertension determine right heart catheterization Pulmonary disease FVC &lt; 45 % predict DLCO ( hemoglobincorrected ) &lt; 40 % predict screen Active state hemoptysis pulmonary hemorrhage , include event manage bronchial artery embolization Not permit prior concomitant medication Pregnant breast feed woman Women childbearing potential willing use adequate contraception willing agree 4weekly pregnancy test Visit 1 ( first administration study drug ) onwards 30 ( +5 ) day last study drug intake .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>